Has Eli Lilly Stock Peaked?
Shares of Eli Lilly have been falling in recent months, but that could spell opportunity. Investors appear to be concerned that a new government could impact its growth potential. The business is in good financial shape but investors may be worried about its high valuation.
GlobalData on MSN1d
JP Morgan 2025: Eli Lilly misses 2024 revenue estimate by $400mEli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.
Six out of 31 total new small molecules approved by the FDA in 2024 were produced by Wuxi, said the company's co-CEO.
Key Takeaways Eli Lilly shares could remain under the microscope on Wednesday after falling sharply Tuesday as the ...
Eli Lilly and Company (NYSE: LLY ... under the microscope on Wednesday after falling sharply Tuesday as the pharmaceutical giant lowered its 2024 full-year forecast. Monitor these key price ...
GlobalData on MSN2d
Eli Lilly targets Scorpion Therapeutics to expand reach in oncologyAfter selling its PI3Kα program to Eli Lilly, Scorpion will spinout out a different entity, which will be owned by the ...
Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...
Analyst Mohit Bansal from Wells Fargo maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target at ...
The shares of pharmaceutical giant Eli Lilly (LLY) are falling 5% today after the company preannounced ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback